Female pattern alopecia: Current perspectives

International Journal of Women's Health

Volumn 5, Issue 1, 2013, Pages 541-556

  Levy, Lauren L ^a   Emer, Jason J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Androgenetic alopecia; Antiandrogens; Female pattern hair loss; Finasteride; Minoxidil; Spironolactone

Indexed keywords

17ALPHA ESTRADIOL; BIMATOPROST; CORTICOSTEROID; CYPROTERONE ACETATE; DUTASTERIDE; EFLORNITHINE; ESTROGEN; ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; FULVESTRANT; GESTODENE; KETOCONAZOLE; LATANOPROST; MINOXIDIL; ORAL CONTRACEPTIVE AGENT; PLACEBO; SPIRONOLACTONE; TRAVOPROST;

ACNE; ALOPECIA; ALOPECIA AREATA; BREAST TENDERNESS; BURNING SENSATION; CHLOASMA; CLINICAL ASSESSMENT; DEPRESSION; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ERYTHEMA; FEMALE; FEMALE PATTERN ALOPECIA; FEMINIZATION; FOLLICULITIS; GLAUCOMA; HAIR TRANSPLANTATION; HEPATITIS; HIRSUTISM; HOT FLUSH; HUMAN; HYPERTRICHOSIS; HYPOTRICHOSIS; INTRAOCULAR HYPERTENSION; LIBIDO DISORDER; LIGHT EMITTING DIODE; LOW LEVEL LASER THERAPY; LUDWIG CLASSIFICATION; MALE TYPE ALOPECIA; MEDICAL DEVICE; MEDICAL LASER DEVICE; MENSTRUAL IRREGULARITY; NAUSEA; NORWOOD HAMILTON CLASSIFICATION; PATHOGENESIS; PHOTOTHERAPY; PIGMENT DISORDER; PROSTATE HYPERTROPHY; REVIEW; SCALP PRURITUS; SEBORRHEA; SIDE EFFECT; SKIN IRRITATION; TELANGIECTASIA; WEIGHT GAIN;

EID: 84883429643     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S49337     Document Type: Review

References (127)

1. Olsen EA, Reed KB, Cacchio PB, Caudill L. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol. 2010;63(6):991-999.
2. Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001;27(1):53-54.
3. Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001;144(2):297-304.
4. Gonzalez ME, Cantatore-Francis J, Orlow SJ. Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients. Br J Dermatol. 2010;163(2):378-385.
5. Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol. 1993;29(4):568-575.
6. Camacho FM, García-Hernández M. Psychological features of androgenetic alopecia. J Eur Acad Dermatol Venereol. 2002;16(5): 476-480.
7. Lesko SM, Rosenberg L, Shapiro S. A case-control study of baldness in relation to myocardial infarction in men. JAMA. 1993;269(8): 998-1003.
8. Shahar E, Heiss G, Rosamond WD, Szklo M. Baldness and myocardial infarction in men: the atherosclerosis risk in communities study. Am J Epidemiol. 2008;167(6):676-683.
9. Oh BR, Kim SJ, Moon JD, etal. Association of benign prostatic hyperplasia with male pattern baldness. Urology. 1998;51(5): 744-748.
10. Faydaci G, Bilal E, Necmettin P, Fatih T, Asuman O, Uǧur K. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels. Aging Male. 2008;11(4):189-192.
11. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97(3): 247-254.
12. Olsen EA, Hordinsky M, Roberts JL, Whiting DA; Dermatologic Consortium for Women's Health. Female pattern hair loss. J Am Acad Dermatol. 2002;47(5):795.
13. Olsen EA. Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. J Am Acad Dermatol. 2003;48(2): 253-262.
14. Birch MP, Lalla SC, Messenger AG. Female pattern hair loss. Clin Exp Dermatol. 2002;27(5):383-388.
15. Sinclair RD, Dawber RP. Androgenetic alopecia in men and women. Clin Dermatol. 2001;19(2):167-178.
16. Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999;4(3):282-284.
17. Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss: clinicopathological correlations. Br J Dermatol. 2006;155(5): 926-930.
18. Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21(5): 314-328.
19. Price VH. Androgenetic alopecia in women. J Investig Dermatol Symp Proc. 2003;8(1):24-27.
20. Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol. 1988;19(5 Pt 1):831-836.
21. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109(3): 296-300.
22. Orme S, Cullen DR, Messenger AG. Diffuse female hair loss: are androgens necessary? Br J Dermatol. 1999;141(3):521-523.
23. Yip L, Rufaut N, Sinclair R. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol. 2011;52(2):81-88.
24. Conrad F, Paus R. Estrogens and the hair follicle. J Dtsch Dermatol Ges. 2004;2(6):412-423.
25. Yip L, Zaloumis S, Irwin D, etal. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol. 2009;161(2):289-294.
26. Zappacosta AR. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med. 1980;303(25):1480-1481.
27. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186-194.
28. Price VH. Treatment of hair loss. N Engl J Med. 1999;341(13): 964-973.
29. Haber RS. Pharmacologic management of pattern hair loss. Facial Plast Surg Clin North Am. 2004;12(2):181-189.
30. Whiting DA, Jacobson C. Treatment of female androgenetic alopecia with minoxidil 2%. Int J Dermatol. 1992;31(11):800-804.
31. Jacobs JP, Szpunar CA, Warner ML. Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol. 1993;32(10): 758-762.
32. Lucky AW, Piacquadio DJ, Ditre CM, etal. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4): 541-553.
33. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6): 1126-1134. e2.
34. van Zuuren EJ, Fedorowicz Z, Carter B, Andriolo RB, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2012;5:CD007628.
35. Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999;41(5 Pt 1):717-721.
36. Johnson and Johnson Consumer and Personal Products Worldwide. A phase 3multi-center parallel design clinical trial to compare the efficacy and safety of 5% minoxidil foam vs 2% minoxidil solution in females for the treatment of female pattern hair loss-androgenetic alopecia. Available from http://clinicaltrials.gov/show/NCT01145625. NLM identifier: NCT01145625. Accessed April 10, 2013.
37. Thuangtong R. Pilot study of the efficacy in treatment of female pattern hair loss using 5% minoxidil solution combined with oral chelated zinc supplement. Available from: http://clinicaltrials.gov/ct2/show/NCT01662089. NLM identifier: NCT01662089. Accessed April 10, 2013.
38. Rafi AW, Katz RM. Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA. ISRN Dermatol. 2011;2011:241953.
39. Hoedemaker C, van Egmond S, Sinclair R. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Australas J Dermatol. 2007;48(1):43-45.
40. Gelfuso GM, Gratieri T, Delgado-Charro MB, Guy RH, Vianna Lopez RF. Iontophoresis-targeted, follicular delivery of minoxidil sulfate for the treatment of alopecia. J Pharm Sci. 2013;102(5):1488-1494.
41. van den Hurk CJ, van den Akker-van Marle ME, Breed WP, van de Poll-Franse LV, Nortier JW, Coebergh JW. Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer. Eur J Oncol Nurs. Epub April 6, 2013.
42. Gormley GJ. Finasteride: a clinical review. Biomed Pharmacother. 1995;49(7-8):319-324.
43. Propecia [package insert]. White House Station, NJ: Merck and Co, Inc; Oct 2004.
44. Proscar [package insert]. White House Station, NJ: Merck and Co, Inc; Jan 2013.
45. Kaufman KD, Olsen EA, Whiting D, etal. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39(4 Pt 1): 578-589.
46. Leyden J, Dunlap F, Miller B, etal. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999;40(6 Pt 1):930-937.
47. Price VH, Roberts JL, Hordinsky M, etal. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 Pt 1):768-776.
48. Yeon JH, Jung JY, Choi JW, etal. 5mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol. 2011;25(2):211-214.
49. Trüeb RM; Swiss Trichology Study Group. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology. 2004;209(3):202-207.
50. Boychenko O, Bernstein RM, Schweiger ES. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature. Cutis. 2012;90(2):73-76.
51. Thai KE, Sinclair RD. Finasteride for female androgenetic alopecia. Br J Dermatol. 2002;147(4):812-813.
52. Valsecchi R, Leghissa P, Riva M. Female androgenetic alopecia treated by finasteride: a case forward. Acta Derm Venereol. 2004;84(6): 488-489.
53. Shum KW, Cullen DR, Messenger AG. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol. 2002;47(5):733-739.
54. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79(1):91-95.
55. Avodart [package insert]. Research Triangle Park, NC: GlaxoSmithKline; Oct 2012.
56. Eun HC, Kwon OS, Yeon JH, etal. Efficacy, safety, and tolerability of dutasteride 0.5mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258.
57. Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. J Cosmet Dermatol. 2007;6(1):9-13.
58. Olsen EA, Hordinsky M, Whiting D, etal; Dutasteride Alopecia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023.
59. Boyapati A, Sinclair R. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia. Australas J Dermatol. 2013;54(1):49-51.
60. Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drug Dermatol. 2005;4(5):637-640.
61. Moftah N, Moftah N, Abd-Elaziz G, etal. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013;27(6):686-693.
62. Sharma P, Jain D, Maithani M, etal. Development and characterization of dutasteride bearing liposomal systems for topical use. Curr Drug Discov Technol. 2011;8(2):136-145.
63. Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010;28(3):611-618.
64. Aldactone [package insert]. New York, NY: Pfizer Inc; Oct 2012.
65. Rathnayake D, Sinclair R. Use of spironolactone in dermatology. Skinmed. 2010;8(6):328-332.
66. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? Facts and controversies. Clin Dermatol. 2010;28(1):17-23.
67. Gómez R, Núñez L, Caballero R, Vaquero M, Tamargo J, Delpón E. Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + mink channels. Br J Pharmacol. 2005;146(1): 146-161.
68. Yazdabadi A, Green J, Sinclair R. Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. Australas J Dermatol. 2009;50(2):113-114.
69. Adamopoulos DA, Karamertzanis M, Nicopoulou S, Gregoriou A. Beneficial effect of spironolactone on androgenic alopecia. Clin Endocrinol (Oxf). 1997;47(6):759-760.
70. Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol. 1985;112(1):124-125.
71. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152(3):466-473.
72. Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril. 2003;79(4): 942-946.
73. Thai KE, Sinclair RD. Spironolactone-induced hepatitis. Australas J Dermatol. 2001;42(3):180-182.
74. Hughes BR, Cunliffe WJ. Tolerance of spironolactone. Br J Dermatol. 1988;118(5):687-691.
75. Brzezińska-Wcisło L. [Assessment of efficacy of Diane-35in androgenetic feminine alopecia.] Wiad Lek. 2003;56(3-4):202-205. Polish.
76. Dinh QQ, Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging. 2007;2(2):189-199.
77. Rushton DH, Ramsay ID. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women. Clin Endocrinol (Oxf). 1992;36(4):421-427.
78. Karrer-Voegeli S, Rey F, Reymond MJ, Meuwly JY, Gaillard RC, Gomez F. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore). 2009;88(1):32-45.
79. Vexiau P, Chaspoux C, Boudou P, etal. Effects of minoxidil 2% vs cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol. 2002;146(6):992-999.
80. Scheinfeld N. A review of hormonal therapy for female pattern (androgenic) alopecia. Dermatol Online J. 2008;14(3):1.
81. Simard J, Luthy I, Guay J, Bélanger A, Labrie F. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol. 1986;44(3):261-270.
82. Paradisi R, Porcu E, Fabbri R, Seracchioli R, Battaglia C, Venturoli S. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011;45(4):469-475.
83. Yazdabadi A, Sinclair R. Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. Australas J Dermatol. 2011;52(2):132-134.
84. Xalatan [package insert]. New York, NY: Pfizer Inc; August 2011.
85. Travatan [package insert]. Fort Worth, TX: Alcon Laboratories Inc; Sep 2011.
86. Lumigan [package insert]. Irivine, CA: Allergan Inc; 2012.
87. Latisse [package insert]. Irivine, CA: Allergan Inc; 2012.
88. Massaki AB, Fabi SG, Fitzpatrick R. Repigmentation of hypopigmented scars using an erbium-doped 1,550-nm fractionated laser and topical bimatoprost. Dermatol Surg. 2012;38(7 Pt 1):995-1001.
89. Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg. 2010;36(9):1361-1371.
90. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47 Suppl 1:S185-S202.
91. Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm Venereol. 2002;82(1):7-12.
92. Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794-800.
93. Emer JJ, Stevenson ML, Markowitz O. Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution. J Drugs Dermatol. 2011;10(7):795-798.
94. Allergan. Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. Available from http://clinicaltrials.gov/ct2/show/NCT01325350. NLM identifier: NCT01325350. Accessed April 9, 2013.
95. Faghihi G, Andalib F, Asilian A. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur J Dermatol. 2009;19(6):586-587.
96. Coronel-Pérez IM, Rodríguez-Rey EM, Camacho-Martínez FM. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol. 2010;24(4):481-485.
97. Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474-477.
98. Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29(8):489-498.
99. Jiang J, Tsuboi R, Kojima Y, Ogawa H. Topical application of ketoconazole stimulates hair growth in C3H/HeN mice. J Dermatol. 2005;32(4):243-247.
100. Debruyne FM, Witjes FA. Ketoconazole high dose (HD) in the management of hormonally pretreated patients with progressive metastatic prostate cancer. Prog Clin Biol Res. 1987;243A:301-313.
101. Conrad F, Paus R. Estrogens and the hair follicle. J Dtsch Dermatol Ges. 2004;2(6):412-423.
102. Yip L, Zaloumis S, Irwin D, etal. Association analysis of oestrogen receptor beta gene (ESR2) polymorphisms with female pattern hair loss. Br J Dermatol. 2012;166(5):1131-1134.
103. Robbins C, Mirmirani P, Messenger AG, etal. What women want-quantifying the perception of hair amount: an analysis of hair diameter and density changes with age in caucasian women. Br J Dermatol. 2012;167(2):324-332.
104. Kondo S, Hozumi Y, Aso K. Organ culture of human scalp hair follicles: effect of testosterone and oestrogen on hair growth. Arch Dermatol Res. 1990;282(7):442-445.
105. Conrad F, Ohnemus U, Bodo E, etal. Substantial sex-dependent differences in the response of human scalp hair follicles to estrogen stimulation in vitro advocate gender-tailored management of female versus male pattern balding. J Investig Dermatol Symp Proc. 2005;10(3):243-246.
106. Mirmirani P. Hormonal changes in menopause: do they contribute to a 'midlife hair crisis' in women? Br J Dermatol. 2011;165 Suppl 3: 7-11.
107. Nissimov J, Elchalal U. Scalp hair diameter increases during pregnancy. Clin Exp Dermatol. 2003;28(5):525-530.
108. Adenuga P, Summers P, Bergfeld W. Hair regrowth in a male patient with extensive androgenetic alopecia on estrogen therapy. J Am Acad Dermatol. 2012;67(3):e121-e123.
109. Gassmueller J, Hoffmann R, Webster A. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. Br J Dermatol. 2008;158(1):109-115.
110. Blume-Peytavi U, Kunte C, Krisp A, Garcia Bartels N, Ellwanger U, Hoffmann R. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. J Dtsch Dermatol Ges. 2007;5(5):391-395.
111. Blumeyer A, Tosti A, Messenger A, etal; European Dermatology Forum (EDF). Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9 Suppl 6:S1-S57.
112. Aoi N, Inoue K, Chikanishi T, etal. 1α, 25-dihydroxyvitamin D3modulates the hair-inductive capacity of dermal papilla cells: therapeutic potential for hair regeneration. Stem Cells Transl Med. 2012;1(8):615-626.
113. Finner AM. Nutrition and hair: deficiencies and supplements. Dermatol Clin. 2013;31(1):167-172.
114. Rajput RJ. Controversy: is there a role for adjuvants in the management of male pattern hair loss? J Cutan Aesthet Surg. 2010;3(2): 82-86.
115. Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59(4):547-566.
116. Limat A, Suormala T, Hunziker T, Waelti ER, Braathen LR, Baumgartner R. Proliferation and differentiation of cultured human follicular keratinocytes are not influenced by biotin. Arch Dermatol Res. 1996;288(1):31-38.
117. Tafur J, Mills PJ. Low-intensity light therapy: exploring the role of redox mechanisms. Photomed Laser Surg. 2008;26(4): 323-328.
118. Avram MR, Rogers NE. The use of low-level light for hair growth: part I. J Cosmet Laser Ther. 2009;11(2):110-117.
119. Oron U, Ilic S, De Taboada L, Streeter J. Ga-As (808nm) laser irradiation enhances ATP production in human neuronal cells in culture. Photomed Laser Surg. 2007;25(3):180-182.
120. Bernstein EF. Hair growth induced by diode laser treatment. Dermatol Surg. 2005;31(5):584-586.
121. Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg. 2009;28(1):15-18.
122. Hairmax. com [homepage on the Internet]. Boca Raton: Lexington International LLC; 2001-2013. Available from: http://www.hairmax.com. Accessed April 11, 2013.
123. Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: a randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig. 2009;29(5):283-292.
124. Satino J. Markou M. Hair regrowth and increased hair tensile strength using the HairMax laser comb for low-level laser therapy. International Journal of Cosmetic Surgery and Aesthetic Dermatology. 2003;5(2):113-117.
125. Kim H, Choi JW, Kim JY, Shin JW, Lee SJ, Huh CH. Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial. Dermatol Surg. Epub April 3, 2013.
126. Unger WP, Unger RH. Hair transplanting: an important but often forgotten treatment for female pattern hair loss. J Am Acad Dermatol. 2003;49(5):853-860.
127. Avram MR, Cole JP, Gandelman M, etal; Roundtable Consensus Meeting of The 9th Annual Meeting of The International Society of Hair Restoration Surgery. The potential role of minoxidil in the hair transplantation setting. Dermatol Surg. 2002;28(10):894-900.